MaxCyte opened higher at $1.11, compared with its previous close of $1.10. In the last trading session, the stock traded between $1.02 and $1.22. It showed an upward intraday trend.
An investment of $100 made 5 years ago in MaxCyte is now worth
$ 9.15
Resulting in a loss of
$ 90.85 (90.85%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
+$0.08 (+7.09%)
Day High
$1.22
Day Low
$1.02
Day Open
$1.11
Prev Close
$1.10
Volume
19,33,477
1W Return
-14.95%
1M Return
18.15%
3M Return
-5.38%
6M Return
44.20%
1Y Return
-24.00%
Market Cap ($ Mn)
122
PE Ratio
-
PB Ratio
0.82
PEG Ratio
-
ROE
-23.54%
ROCE
-25.08%
EPS (TTM)
$-0.08
1 Week
-14.95%
1 Month
18.15%
3 Months
-5.38%
6 Months
44.20%
9 Months
61.33%
MaxCyte Q3FY26 Results: Loss narrows to $(0.05), sales up 48.66% YoY
Q3 loss per share narrowed to $(0.05), beating consensus estimates by 37.5%. Revenue rose 48.66% YoY to $10.152 million, exceeding estimates by 35.71%. Announced definitive agreement to acquire Akron Bio for $151.8 million. Full-year 2026 revenue guidance raised to at least $34.5 million. Acquisition expected to nearly double revenue base and cut cash burn below $10 million in 2027.
2 days agoLiontrust discloses 5% stake in MaxCyte Inc as of Oct 14
Liontrust Investment Partners reported a 5% stake in MaxCyte Inc. The disclosure was made via a Schedule 13D filing. The reporting date for the stake is October 14.
28 days agoMaxCyte launches CHANGE-seq-BE and ONE-seq-BE off-target assays
MaxCyte, Inc. (NASDAQ: MXCT) launched the CHANGE-seq-BE and ONE-seq-BE off-target nomination assays via its SeQure service. These assays provide sensitive nomination of off-target sites for adenine and cytosine base editors. CEO Maher Masoud stated the tools help developers build stronger data packages for clinical development.
2mo agoMaxCyte narrows Q2 2026 loss 28%, signs Genentech deal
MaxCyte Inc reported Q2 2026 revenue of $7.3 million, down 15% YoY, but narrowed net loss to $8.9 million from $12.4 million. The company beat analyst estimates on EPS and revenue. Key developments include a new multi-platform license partnership with Genentech and $5.5 million in stock repurchases. Full year 2026 revenue guidance remains at $30-32 million.
3mo agoMaxCyte affirms FY26 sales guidance of $30M-$32M vs estimate
MaxCyte Inc. reaffirmed its FY2026 sales guidance of $30.000 million to $32.000 million, unchanged from prior periods. The outlook aligns with the $31.082 million analyst estimate, indicating stable revenue expectations for the biotech firm.
3mo agoMaxCyte licenses ExPERT GTx platform to Genentech for cell therapy
MaxCyte, Inc. has partnered with Genentech to license its ExPERT GTx platform for cell therapy development. The agreement spans research, clinical, and manufacturing workflows, aiming to streamline the advancement of multiple programs.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 5 years ago in MaxCyte is now worth
$ 9.15
Resulting in a loss of
$ 90.85 (90.85%)
Note: Past profits do not guarantee future returns.
